Related Experiment Video
Updated: Mar 12, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
Platelet Integrin αIIbβ3 Inhibitor Rescues Progression of Apoptosis in Human Platelets
Jie Zhu1, Qinghang Wang1, Yumei Nie1
1Department of Cardiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China (mainland).
Abstract:
BACKGROUND Apoptosis plays an important role in the physiology of platelet function. We aimed to detect the effect of the platelet integrin αIIbβ3 inhibitor, tirofiban, on apoptotic events, including mitochondrial inner-membrane potential (ΔΨm), phosphatidylserine (PS) exposure on platelet surface, and the generation of reactive oxygen species (ROS), when washed platelets were stimulated with thrombin. MATERIAL AND METHODS The study included washed platelets from healthy humans, divided into 4 groups: vehicle, and tirofiban (0.05 μg/ml, 0.25 μg/ml, and 0.5 μg/ml). Platelets were pretreated with vehicle or tirofiban and incubated at 37°C with agitation for 6 h and 24 h. Before thrombin addition, the vehicle group divided into 2 equal groups. Except one vehicle group, the other 4 groups were all stimulated with thrombin (1 U/ml) for 30 min at 37°C. Using flow cytometry, we studied the DYm and PS exposure on platelet surfaces, and the generation of ROS in platelets. RESULTS We observed that at the time of 6 h and 24 h, thrombin-stimulated vehicle platelets induced significant depo-larization of ΔΨm, higher PS exposure, and increased ROS production compared with the vehicle group (P<0.01). However, the tirofiban group had significantly more recovery of DYm, PS exposure, and ROS production compared with the thrombin group (P<0.01). CONCLUSIONS The platelet integrin αIIbβ3 inhibitor, tirofiban, inhibits the depolarization of DYm, PS exposure on platelet surface, and ROS production when stimulated with thrombin. These results suggest that αIIbβ3 inhibitor inhibits the initiation of apoptosis in platelets, showing a potential clinical application of tirofiban as an apoptosis inhibitor.
Insights
Tirofiban, a platelet integrin inhibitor, significantly reduces apoptosis markers like mitochondrial depolarization and reactive oxygen species in thrombin-stimulated platelets. This suggests tirofiban may act as an apoptosis inhibitor in platelets with potential clinical applications.
Area of Science:
- Hematology
- Cell Biology
- Pharmacology
Background:
- Apoptosis is crucial in platelet physiology.
- Platelet integrin αIIbβ3 plays a role in platelet activation and apoptosis.
- Tirofiban is an inhibitor of platelet integrin αIIbβ3.
Purpose of the Study:
- To investigate the effect of tirofiban on platelet apoptosis.
- To assess tirofiban's impact on mitochondrial membrane potential (ΔΨm), phosphatidylserine (PS) exposure, and reactive oxygen species (ROS) generation.
- To determine if tirofiban inhibits thrombin-induced platelet apoptosis.
Main Methods:
- Washed human platelets were used.
- Platelets were pretreated with tirofiban or vehicle, then stimulated with thrombin.
- Flow cytometry was employed to measure ΔΨm, PS exposure, and ROS production at 6 and 24 hours.
Main Results:
- Thrombin stimulation significantly induced ΔΨm depolarization, PS exposure, and ROS production in vehicle-treated platelets.
- Tirofiban treatment significantly attenuated these apoptotic markers compared to thrombin-stimulated platelets.
- Tirofiban demonstrated a dose-dependent recovery of ΔΨm, reduced PS exposure, and decreased ROS production.
Conclusions:
- Tirofiban inhibits key apoptotic events in thrombin-activated platelets.
- The αIIbβ3 inhibitor effectively reduces mitochondrial dysfunction, PS externalization, and ROS generation.
- Tirofiban shows potential as a clinical agent to inhibit platelet apoptosis.
Related Concept Videos
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Intracellular Signaling Affects Focal Adhesions
Some...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis
Peripheral Artery Disease III: Interprofessional Care
Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...

